.

ISSN 2063-5346
For urgent queries please contact : +918130348310

DEVELOPMENT AND EVALUATION OF PRAZIQUANTEL LEADED CHEWABLE TABLET FOR TREATMENT OF HELMINTHIASIS

Main Article Content

Krithiga Venkatesan, Damodharan Narayanaswamy
» doi: 10.31838/ecb/2023.12.s2.108

Abstract

Nearly a billion people are affected with helminthiasis, a category of parasitic illnesses caused by different worms, mostly in developing countries with inadequate sanitation and hygiene. These infections may have long-term impacts on the physical and cognitive development of children and induce symptoms such as abdominal discomfort, diarrhea, anemia, and malnutrition. Despite the fact that helminthiasis may be treated with anthelmintic drugs such as albendazole, mebendazole, and praziquantel, its prevention needs a multidisciplinary strategy that includes better sanitation, hygiene, and health education. Chewable tablets are advantageous for those who have difficulties swallowing pills or capsules since they may be chewed before ingesting, giving them a more convenient and appetizing treatment alternative. They are available in grape, cherry, and orange tastes, which may encourage patients to take their drugs more often and lower the chance of adverse reactions. Chewable praziquantel tablets may be more successful than regular tablets or capsules in treating parasitic illnesses such as schistosomiasis and tapeworms. Chewable praziquantel tablets have been proven to have a greater bioavailability and quicker absorption rate than regular pills, resulting in better treatment results. In order to improve medication compliance and treatment success for parasitic infection, we have designed and evaluated chewable praziquantel tablets using direct compression method.

Article Details